Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Feb 20:6:28.
doi: 10.1186/1471-2334-6-28.

A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people

Jeffrey T Schouten  1 , David W Lockhart, Thomas S Rees, Ann C Collier, Christina M Marra
Affiliations
Clinical Trial

A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people

Jeffrey T Schouten et al. BMC Infect Dis. .

Abstract

Background: While hearing loss in HIV-infected people after beginning nucleoside reverse transcriptase inhibitors (NRTIs) has been reported, there have been no prospective studies that measured hearing changes longitudinally in treatment-naïve HIV-infected subjects following initiation of regimens containing NRTIs. The goal of this study was to conduct a prospective assessment of the contribution of zidovudine (ZDV) and didanosine (ddI) to hearing loss.

Methods/design: A prospective observational pilot study to determine whether ZDV or ddI, alone or in combination, are associated with sensorineural hearing loss in HIV-infected persons. Changes in hearing levels at all frequencies and in low and high frequency pure tone averages were measured at baseline, 16, and 32 weeks after initiating antiretroviral therapy.

Discussion: Treatment with ZDV and ddI did not result in loss of hearing, even after taking into account noise exposure, immune status and age. The results of this prospective pilot study do not support the notion that treatment with nucleoside antiretrovirals damages hearing.

PubMed Disclaimer

References

    1. Marra CM, Wechkin HA, Longstreth WT, Rees T, Syapin CL, Gates GA. Hearing loss and antiretroviral therapy in patients infected with HIV-1. Arch Neurol. 1997;54:407–410. - PubMed
    1. Simdon J, Watters D, Bartlett S, Connick E. Ototoxicity associated with use of nucleoside analog Reverse transcriptase inhibitors: A report of 3 possible cases and review of the literature. CID. 2001;32:1623–7. doi: 10.1086/320522. - DOI - PubMed
    1. McNaghten AD, Wan PT, Dworkin MS. Correspondence: Prevalence of hearing loss in a cohort of HIV-infected patients. Arch Otolaryngol Head Neck Surg. 2001;127:1516–1518. - PubMed
    1. Lalwani AK, Sooy CD. Otologic and neurotologic manifestations of acquired immunodeficiency virus infection. Otolaryngol Clin North Am. 1992;25:1183–97.
    1. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000;22:685–708. doi: 10.1016/S0149-2918(00)90004-3. - DOI - PubMed

Publication types